The disruption of ZMIZ2 in tumor tissues of both SBL and HB may lead to down-regulation of β-catenin downstream targets and inhibition of the Wnt signaling pathway after treatment (Figure 4B). This evidence concerns the gene ZMIZ2 and neoplasm.